- VANUDIS - Biotech Company
- SkyAngle Building
- Max-Jarecki-Str. 21
- 69115 Heidelberg
- office@vanudis.net
- +49 6221 3919 0
ImmunoRNAses
Antibody-targeted delivery of ribonucleases as effector moieties for selective killing of tumor cells
A further core competence of VANUDIS is the generation of antibody-based therapeutics with extended effector functions.
In particular, the founders of VANUDIS have a long-standing expertise in the preclinical development of such compounds by employing radionuclides and amphibian and human ribonucleases as cytotoxic effector components.
The key-advantage of using ribonucleases as effector moieties for antibody-based immunotherapeutics is their significantly lower immunogenic and toxic potential when compared with classical antibody drug conjugates (ADCs).